{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:20:19Z","timestamp":1791498019494,"version":"4.3.4"},"reference-count":50,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["175:1298-304"],"award-info":[{"award-number":["175:1298-304"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jaip.2025.02.040","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T12:24:18Z","timestamp":1741695858000},"page":"1164-1175.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Long-Term Safety of Abrocitinib in Moderate-to-Severe Atopic Dermatitis: Integrated Analysis by Age"],"prefix":"10.1016","volume":"13","author":[{"given":"Michael J.","family":"Cork","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette","family":"Deleuran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bob","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan I.","family":"Silverberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda F.","family":"Stein Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D.","family":"Irvine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hernan","family":"Valdez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3006-1675","authenticated-orcid":false,"given":"Justine","family":"Alderfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2025.02.040_bib1","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jaad.2017.08.002","article-title":"The burden of atopic dermatitis in US adults: health care resource utilization data from the 2013 National Health and Wellness Survey","volume":"78","author":"Eckert","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2025.02.040_bib2","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","article-title":"Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study","volume":"121","author":"Silverberg","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2025.02.040_bib3","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2147\/ITT.S229667","article-title":"Emerging role of Janus kinase inhibitors for the treatment of atopic dermatitis","volume":"9","author":"Singh","year":"2020","journal-title":"Immunotargets Ther"},{"key":"10.1016\/j.jaip.2025.02.040_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-018-0001-z","article-title":"Atopic dermatitis","volume":"4","author":"Weidinger","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jaip.2025.02.040_bib5","series-title":"Cibinqo (abrocitinib) tablets, for oral use. Prescribing information","year":"2022"},{"key":"10.1016\/j.jaip.2025.02.040_bib6","series-title":"Summary of product characteristics","year":"2022"},{"key":"10.1016\/j.jaip.2025.02.040_bib7","series-title":"Summary of product characteristics","year":"2022"},{"key":"10.1016\/j.jaip.2025.02.040_bib9","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2025.02.040_bib10","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40744-022-00505-1","article-title":"Evaluation of VTE, MACE, and serious infections among patients with RA treated with baricitinib compared to TNFi: a multi-database study of patients in routine care using disease registries and claims databases","volume":"10","author":"Salinas","year":"2023","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.jaip.2025.02.040_bib11","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","article-title":"Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial","volume":"156","author":"Silverberg","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaip.2025.02.040_bib12","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","article-title":"Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"396","author":"Simpson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2025.02.040_bib13","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1001\/jamadermatol.2021.2830","article-title":"Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: the JADE TEEN randomized clinical trial","volume":"157","author":"Eichenfield","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaip.2025.02.040_bib14","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaad.2021.05.075","article-title":"Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial","volume":"86","author":"Blauvelt","year":"2022","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2025.02.040_bib15","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1001\/jamadermatol.2019.2855","article-title":"Efficacy and safety of oral Janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial","volume":"155","author":"Gooderham","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaip.2025.02.040_bib16","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","article-title":"Abrocitinib versus placebo or dupilumab for atopic dermatitis","volume":"384","author":"Bieber","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2025.02.040_bib17","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0140-6736(22)01199-0","article-title":"Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial","volume":"400","author":"Reich","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2025.02.040_bib18","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1111\/jdv.19254","article-title":"Abrocitinib effect on patient-reported outcomes in patients with moderate-to-severe atopic dermatitis: results from phase 3 studies, including the long-term extension JADE EXTEND study","volume":"37","author":"Reich","year":"2023","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaip.2025.02.040_bib19","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1111\/jdv.19280","article-title":"Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: results from phase 3 studies, including the long-term extension JADE EXTEND study","volume":"37","author":"Reich","year":"2023","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaip.2025.02.040_bib20","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1111\/all.15969","article-title":"Effect of abrocitinib on skin biomarkers in patients with moderate-to-severe atopic dermatitis","volume":"79","author":"Guttman-Yassky","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.02.040_bib21","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s40257-021-00618-3","article-title":"Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis from the phase II and phase III clinical trial program","volume":"22","author":"Simpson","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaip.2025.02.040_bib22","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s40257-024-00869-w","article-title":"Integrated safety update of abrocitinib in 3802 patients with moderate-to-severe atopic dermatitis: data from more than 5200 patient-years with up to 4 years of exposure","volume":"25","author":"Simpson","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaip.2025.02.040_bib23","first-page":"95","article-title":"Varicella-zoster virus infection: natural history, clinical manifestations, immunity and current and future vaccination strategies","volume":"41","author":"Freer","year":"2018","journal-title":"New Microbiol"},{"key":"10.1016\/j.jaip.2025.02.040_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-004833","article-title":"Systematic review of incidence and complications of herpes zoster: towards a global perspective","volume":"4","author":"Kawai","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.jaip.2025.02.040_bib25","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1161\/STROKEAHA.120.031659","article-title":"Sex, age, and socioeconomic differences in nonfatal stroke incidence and subsequent major adverse outcomes","volume":"52","author":"Akyea","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.jaip.2025.02.040_bib26","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1001\/archinte.158.6.585","article-title":"Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study","volume":"158","author":"Silverstein","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jaip.2025.02.040_bib27","first-page":"e137","article-title":"Short-term efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis stratified by age","volume":"186","author":"Alexis","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2025.02.040_bib28","doi-asserted-by":"crossref","first-page":"i34","DOI":"10.1093\/rheumatology\/key287","article-title":"Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis","volume":"58","author":"Harigai","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaip.2025.02.040_bib29","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1136\/ard-2022-222405","article-title":"Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial","volume":"81","author":"Balanescu","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaip.2025.02.040_bib30","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.jaad.2022.01.009","article-title":"AAD Guidelines: awareness of comorbidities associated with atopic dermatitis in adults","volume":"86","author":"Davis","year":"2022","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2025.02.040_bib31","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.anai.2017.10.019","article-title":"Association between atopic dermatitis and serious cutaneous, multiorgan and systemic infections in US adults","volume":"120","author":"Narla","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2025.02.040_bib32","doi-asserted-by":"crossref","first-page":"ii24","DOI":"10.1093\/rheumatology\/keaa895","article-title":"The safety of JAK-1 inhibitors","volume":"60","author":"Clarke","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaip.2025.02.040_bib33","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/bjd.20887","article-title":"Risk of herpesvirus, serious and opportunistic infections in atopic dermatitis: a population-based cohort study","volume":"186","author":"Wan","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2025.02.040_bib34","series-title":"Summary of product characteristics","year":"2023"},{"key":"10.1016\/j.jaip.2025.02.040_bib35","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1111\/all.14853","article-title":"Eczema herpeticum in atopic dermatitis","volume":"76","author":"Tradil","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2025.02.040_bib36","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3324\/haematol.2010.029934","article-title":"Analysis of 12,517 inhabitants of a Sardinian geographic isolate reveals that predispositions to thrombocytopenia and thrombocytosis are inherited traits","volume":"96","author":"Biino","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.jaip.2025.02.040_bib37","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.annepidem.2005.06.052","article-title":"Platelet counts differ by sex, ethnicity, and age in the United States","volume":"16","author":"Segal","year":"2006","journal-title":"Ann Epidemiol"},{"key":"10.1016\/j.jaip.2025.02.040_bib38","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/sji.12413","article-title":"Effects of ageing on the immune system: infants to elderly","volume":"83","author":"Valiathan","year":"2016","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.jaip.2025.02.040_bib39","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.clim.2018.04.002","article-title":"Immune senescence, epigenetics and autoimmunity","volume":"196","author":"Ray","year":"2018","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaip.2025.02.040_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fragi.2022.900028","article-title":"Immune senescence, immunosenescence and aging","volume":"3","author":"Lee","year":"2022","journal-title":"Front Aging"},{"key":"10.1016\/j.jaip.2025.02.040_bib41","article-title":"U.S. Cancer Statistics Data Visualizations Tool, Based on 2022 Submission Data (1999\u20132020): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute","year":"2023","journal-title":"US Cancer Statistics Working Group"},{"key":"10.1016\/j.jaip.2025.02.040_bib42","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jamaoncol.2019.2996","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the Global Burden of Disease Study","volume":"5","author":"Fitzmaurice","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jaip.2025.02.040_bib43","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-071172","article-title":"Rates of malignancies among patients with moderate to severe atopic dermatitis: a retrospective cohort study","volume":"13","author":"Hedderson","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.jaip.2025.02.040_bib44","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s11357-021-00486-z","article-title":"Cardiovascular risk prediction in healthy older people","volume":"44","author":"Neumann","year":"2022","journal-title":"Geroscience"},{"key":"10.1016\/j.jaip.2025.02.040_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0277469","article-title":"Rates of cardiovascular events among patients with moderate-to-severe atopic dermatitis in an integrated health care system: a retrospective cohort study","volume":"17","author":"Hedderson","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.jaip.2025.02.040_bib46","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nrcardio.2015.83","article-title":"Epidemiology of venous thromboembolism","volume":"12","author":"Heit","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jaip.2025.02.040_bib47","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s13555-021-00538-4","article-title":"Risk of venous thromboembolism among patients with atopic dermatitis: a cohort study in a US administrative claims database","volume":"11","author":"Meyers","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jaip.2025.02.040_bib48","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001395","article-title":"Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme","volume":"6","author":"Cohen","year":"2020","journal-title":"RMD Open"},{"key":"10.1016\/j.jaip.2025.02.040_bib49","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.7573\/dic.2020-8-5","article-title":"Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib","volume":"9","author":"Nezamololama","year":"2020","journal-title":"Drugs Context"},{"key":"10.1016\/j.jaip.2025.02.040_bib50","first-page":"455","article-title":"Rheumatoid arthritis: common questions about diagnosis and management","volume":"97","author":"Wasserman","year":"2018","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.jaip.2025.02.040_bib51","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.7326\/M22-1460","article-title":"Good Publication Practice (GPP) guidelines for company-sponsored biomedical research: 2022 update","volume":"175","author":"DeTora","year":"2022","journal-title":"Ann Intern Med"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219825002132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219825002132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T13:17:39Z","timestamp":1762607859000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219825002132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2213219825002132"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2025.02.040","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-Term Safety of Abrocitinib in Moderate-to-Severe Atopic Dermatitis: Integrated Analysis by Age","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2025.02.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}